SEARCH:   Advanced

Blood, 15 March 2008, Vol. 111, No. 6, pp. 3183-3189. Prepublished online as a Blood First Edition Paper on January 10, 2008; DOI 10.1182/blood-2007-07-098749. This Article Full Text Full Text (PDF) Supplemental Tables More Supplemental Tables and Supplemental Figures All Versions of this Article: blood-2007-07-098749v1 111/6/3183    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Google Scholar Articles by Garzon, R. Articles by Croce, C. M. PubMed PubMed Citation Articles by Garzon, R. Articles by Croce, C. M. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia Ramiro Garzon1, Stefano Volinia2,3, Chang-Gong Liu3, Cecilia Fernandez-Cymering3, Tiziana Palumbo3, Flavia Pichiorri3, Muller Fabbri3, Kevin Coombes4, Hansjuerg Alder3, Tatsuya Nakamura3, Neal Flomenberg5, Guido Marcucci1, George A. Calin6, Steven M. Kornblau7, Hagop Kantarjian8, Clara D. Bloomfield1, Michael Andreeff7, and Carlo M. Croce3 1 Division of Hematology and Oncology, Department of Internal Medicine, Comprehensive Cancer Center, Ohio State University, Columbus; 2 DAMA, Data Mining of DNA Microarrays, University of Ferrara, Ferrara, Italy; 3 Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, Ohio State University, Columbus; 4 Biostatistics Division, M. D. Anderson Cancer Center, Texas State University, Houston; 5 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA; 6 Experimental Therapeutics & Cancer Genetics, 7 Section of Molecular Hematology and Therapy, Department of Blood and Bone Marrow Transplantation, and 8 Department of Leukemia, M. D. Anderson Cancer Center, Texas State University, Houston MicroRNAs (miRNAs) are small RNAs of 19 to 25 nucleotides that are negative regulators of gene expression. To determine whether miRNAs are associated with cytogenetic abnormalities and clinical features in acute myeloid leukemia (AML), we evaluated the miRNA expression of CD34+ cells and 122 untreated adult AML cases using a microarray platform. After background subtraction and normalization using a set of housekeeping genes, data were analyzed using Significance Analysis of Microarrays. An independent set of 60 untreated AML patients was used to validate the outcome signatures using real-time polymerase chain reaction. We identified several miRNAs differentially expressed between CD34+ normal cells and the AML samples. miRNA expression was also closely associated with selected cytogenetic and molecular abnormalities, such as t(11q23), isolated trisomy 8, and FLT3-ITD mutations. Furthermore, patients with high expression of miR-191 and miR-199a had significantly worse overall and event-free survival than AML patients with low expression (overall survival: miR-191, P = .03; and miR-199a, P = .001, Cox regression). In conclusion, miRNA expression in AML is closely associated with cytogenetics and FLT3-ITD mutations. A small subset of miRNAs is correlated with survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: W. Blum Post-remission therapy in acute myeloid leukemia: what should I do now? Haematologica, June 1, 2008; 93(6): 801 - 805. [Full Text] [PDF] B. Lowenberg Diagnosis and Prognosis in Acute Myeloid Leukemia -- The Art of Distinction N. Engl. J. Med., May 1, 2008; 358(18): 1960 - 1962. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020